Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs BR-55 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors Bracco Diagnostics
- 15 Aug 2018 Status changed from not yet recruiting to recruiting.
- 30 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jul 2018.
- 11 Apr 2018 New trial record